US Bancorp
ALGS icon

US Bancorp’s Aligos Therapeutics ALGS Stock Holding History

US Bancorp’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-72
Closed -$4K – 4062
2022
Q1 		$4K Buy
72
+29
+67% +$2.32K ﹤0.01% 3653
2021
Q4 		$13K Buy
43
+26
+153% +$9.48K ﹤0.01% 3307
2021
Q3 		$6K Buy
17
+16
+1,600% +$6.33K ﹤0.01% 3573
2021
Q2 		$0 Buy
+1
New +$637 ﹤0.01% 3984

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

US Bancorp's ALGS Position: Q2 2022 in Review

US Bancorp sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 72 shares — an estimated $4K sold.

US Bancorp first reported a position in ALGS in Q2 2021 and held it in 4 quarters. The position peaked at $13K in Q4 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • US Bancorp reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • US Bancorp sold 72 Aligos Therapeutics shares in Q2 2022, an estimated $4K.
  • US Bancorp first reported a position in Aligos Therapeutics in Q2 2021 and held it in 4 quarters.
  • US Bancorp's Aligos Therapeutics position peaked at $13K in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.